Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$19.98MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Oguz Alper Oktem
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 473
- Beta
- 0.36
- Country
- TR
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -6.85
Financials
Revenue
$19.98M+487.9%Net Income
$-12.50MEBITDA
$5.48MFree Cash Flow
$2.99MEPS (diluted)
$-0.15Shares Outstanding (diluted)
86.13M+379.3%Operating Expenses
$10.45MCash & Debt
$12.50MReturn of Capital
$0.00Revenue by Segment (annual)
$593.7KDividend per Share
$0.21Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $39.24M | $-41.45M | $-0.53 |
| 2024 | $18.66M | $-73.88M | $-1.25 |
| 2023 | $20.03M | $-33.81M | $-0.67 |
| 2022 | $24.99M | $-14.25M | $-0.32 |
| 2021 | $17.00M | $-14.47M | $-0.42 |
| 2020 | $9.76M | $-4.63M | $-0.10 |
Valuation
MRThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (12)
- Newsmarketbeat.com·7h ago·Positive
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study showed sustained degradation of NEK7, reductions in inflammatory and atherogenic biomarkers, and a safety profile comparable with placebo.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis…
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m.
View source ↗ - Newsbusinesswire.com·26d ago·Neutral
…xtends Program Through April 2027 ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced that its Board of Directors (the “Board”) has increased the authorization under the Company's share repurchase program (the “Repurchase Program”) from $2.5 million to $5.0 million and extended the Repurchase Program through April 26, 2027.The expanded authorization reflects Marti's continued commitment to discip…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potent…
View source ↗ - Newsbusinesswire.com·33d ago·Negative
…ers, Exceeding September 30, 2026 Targets a Month Earlier Than Planned ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of September 2, 2026, Marti's ride-hailing service has reached 4.90 million riders and 584 thousand registered drivers, exceeding the September 30, 2026 targets of 4.90 million riders and 580 thousand registered drivers.Marti's number of ride-hailing riders grew 85%…
View source ↗ - Newsseekingalpha.com·42d ago·Neutral
Marti Technologies: Buy The Inflection Point Marti Technologies (MRT) delivered a major operating inflection, turning adjusted EBITDA positive and expanding gross margin to 77%, while accelerating revenue growth. I maintain a speculative buy rating with a $3.88 price target, but highlight that convertible debt implies upside should be viewed on a fully diluted basis. Regulatory uncertainty, balance sheet risks, and potential competition threaten margins and limit de-risking despite strong operat…
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·48d ago·Neutral
Marti Technologies H1 Earnings Call Highlights Marti Technologies NYSEAMERICAN: MRT reported second-quarter 2026 revenue growth of 141% year over year to nearly $20 million and reached positive adjusted EBITDA for the first time, as its ride-hailing marketplace expanded and costs rose more slowly than revenue.
View source ↗ - Newsbusinesswire.com·50d ago·Neutral
Marti Technologies, Inc. to Report 2026 Second Quarter Results on August 19, 2026 ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti”) (NYSE American: MRT), Türkiye's leading mobility super app, will announce its financial and operational results for the quarter ended June 30, 2026 (“2026 Second Quarter Results”) before the U.S. markets open on Wednesday, August 19, 2026. Conference Call and Webcast Details Marti's management will host an analyst and investor conference call and live we…
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
Marti Technologies Launches Ride-Hailing Service in 10 New Cities Across Türkiye ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, today announced the launch of its ride-hailing service in 10 additional cities across Türkiye, expanding Marti's ride-hailing footprint to 30 cities and approximately 85% of Türkiye's GDP. Marti is expanding its ride-hailing service in response to demand, supply, and growth rates
View source ↗
Earnings
Wed, Nov 18(in 6 weeks)
Consensus estimate $-0.04 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-0.15 vs $-0.07miss
- Thu, May 21$-0.09 vs $-0.35beat
- Mon, Apr 13$-0.29 vs $-0.29beat
- Mon, Sep 29$-0.13 vs $-0.31beat
- Mon, Sep 22$-0.28 vs $-0.31beat
- Tue, Apr 29$-0.88 vs $-0.37miss
Estimates and results for MRT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MRT officers and directors.
- Bought
- —
- Sold
- $21.4m
0 trades
66 trades
- Freifeld Danielsold
- Freifeld Danielsold
- Freifeld Danielsold
- Bluemountain Capital Management, Llcsold
- Bluemountain Capital Management, Llcsold
- Bluemountain Capital Management, Llcsold
- Bluemountain Capital Management, Llcsold
- Bluemountain Capital Management, Llcsold
34 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Greg Gianfortehouse · MT00 · disclosed Jan 23, 2019 (33d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.